Aclaris Therapeutics Inc - Asset Resilience Ratio
Aclaris Therapeutics Inc (ACRS) has an Asset Resilience Ratio of 40.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Aclaris Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Aclaris Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Aclaris Therapeutics Inc (ACRS) total assets.
Liquid Assets Composition Over Time
This chart breaks down Aclaris Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Aclaris Therapeutics Inc (ACRS) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $70.66 Million | 40.25% |
| Total Liquid Assets | $70.66 Million | 40.25% |
Asset Resilience Insights
- Very High Liquidity: Aclaris Therapeutics Inc maintains exceptional liquid asset reserves at 40.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aclaris Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Aclaris Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Aclaris Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 40.41% | $89.02 Million | $220.33 Million | +0.27pp |
| 2023-12-31 | 40.13% | $79.23 Million | $197.41 Million | -27.54pp |
| 2022-12-31 | 67.67% | $172.29 Million | $254.60 Million | +2.36pp |
| 2021-12-31 | 65.31% | $164.06 Million | $251.21 Million | +20.01pp |
| 2020-12-31 | 45.30% | $32.07 Million | $70.78 Million | +5.55pp |
| 2019-12-31 | 39.76% | $39.08 Million | $98.30 Million | -0.51pp |
| 2018-12-31 | 40.26% | $110.95 Million | $275.57 Million | -31.05pp |
| 2017-12-31 | 71.31% | $173.66 Million | $243.51 Million | +10.52pp |
| 2016-12-31 | 60.80% | $107.05 Million | $176.09 Million | -18.95pp |
| 2015-12-31 | 79.74% | $75.02 Million | $94.08 Million | +48.82pp |
| 2014-12-31 | 30.92% | $5.37 Million | $17.38 Million | +4.62pp |
| 2013-12-31 | 26.30% | $3.74 Million | $14.21 Million | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more